OCM
XERS icon

Ovata Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Ovata Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,200
Closed -$6K – 147
2022
Q1 		$6K Buy
+2,200
New +$5.37K ﹤0.01% 136

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ovata Capital Management's XERS Position: Q2 2022 in Review

Ovata Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 2,200 shares — an estimated $6K sold.

Ovata Capital Management first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

  • Ovata Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • Ovata Capital Management sold 2,200 Xeris Biopharma Holdings shares in Q2 2022, an estimated $6K.
  • Ovata Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
  • Ovata Capital Management's Xeris Biopharma Holdings position peaked at $6K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on Ovata Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.